Literature DB >> 24898679

Inflammation and peripheral venous disease. The San Diego Population Study.

M Cushman1, P W Callas, M A Allison, M H Criqui.   

Abstract

The inflammatory response to healing in venous thrombosis might cause vein damage and post-thrombotic syndrome. Inflammation may also be involved in venous insufficiency apart from deep-vein thrombosis. We studied the association of inflammation markers with venous insufficiency in a general population sample. We characterised 2,404 men and women in a general population cohort for peripheral venous disease and its severity using physical exam, symptom assessment, and venous ultrasound. Inflammation markers, C-reactive protein (CRP), fibrinogen, interleukin 1-beta (IL-1-beta), IL-8, IL-10, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, monocyte chemoattractant-1 (MCP-1) and vascular endothelial cell growth factor (VEGF) were compared in 352 case participants with peripheral venous disease and 352 controls with no venous abnormalities frequency matched to cases by age, sex and race. Associations were also evaluated including a subset of 108 cases of severe venous disease, as previously defined. Odds ratios (95% CI), for peripheral venous disease for biomarkers in the top quartile (adjusting for age, race, sex, body mass index and history of venous thrombosis) were 1.8 (1.1-3.0), 1.6 (1.0-2.5) and 1.5 (0.9-2.3) for CRP, fibrinogen and IL-10, respectively. Associations were larger considering cases of severe venous disease, with odds ratios for these three analytes of 2.6 (1.2-5.9), 3.1 (1.3-7.3) and 2.2 (1.1-4.4), and for IL-8: 2.4 (1.1-5.2). There was no association of IL-1-beta, ICAM-1, VCAM-1, E-selectin, MCP-1 or VEGF with overall cases or severe venous disease. In conclusion, a subset of inflammation markers were associated with increased risk of peripheral venous disease, suggesting potential therapeutic targets for treatment.

Entities:  

Keywords:  Inflammation; risk factor; venous disease; venous insufficiency

Mesh:

Substances:

Year:  2014        PMID: 24898679     DOI: 10.1160/TH13-10-0860

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

1.  Gram-Negative Pneumonia Alters Large-Vein Cell-Adhesion Molecule Profile and Potentiates Experimental Stasis Venous Thrombosis.

Authors:  Andrea T Obi; Elizabeth Andraska; Yogendra Kanthi; Catherine E Luke; Megan Elfline; Suresh Madathilparambil; Teruna J Siahaan; Farouc A Jaffer; Thomas W Wakefield; Krishnan Raghavendran; Peter K Henke
Journal:  J Vasc Res       Date:  2016-10-22       Impact factor: 1.934

2.  Inflammatory signals and network connections implicate cell-mediated immunity in chronic venous insufficiency.

Authors:  Lena Vodovotz; Ruben Zamora; Derek A Barclay; Yoram Vodovotz; Jinling Yin; Julie Bitner; John Florida; Efthymios D Avgerinos; Ulka Sachdev
Journal:  Ann Transl Med       Date:  2021-11

Review 3.  P- and E- selectin in venous thrombosis and non-venous pathologies.

Authors:  Megan Purdy; Andrea Obi; Daniel Myers; Thomas Wakefield
Journal:  J Thromb Haemost       Date:  2022-03-25       Impact factor: 16.036

4.  Resting heart rate and incidence of venous thromboembolism.

Authors:  Aaron R Folsom; Pamela L Lutsey; Zachary C Pope; Oluwaseun E Fashanu; Jeffrey R Misialek; Mary Cushman; Erin D Michos
Journal:  Res Pract Thromb Haemost       Date:  2019-12-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.